157 related articles for article (PubMed ID: 32497566)
1. The search for opioid analgesics with limited tolerance liability.
Wtorek K; Piekielna-Ciesielska J; Janecki T; Janecka A
Peptides; 2020 Aug; 130():170331. PubMed ID: 32497566
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
3. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
[TBL] [Abstract][Full Text] [Related]
5. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
[TBL] [Abstract][Full Text] [Related]
6. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
[TBL] [Abstract][Full Text] [Related]
7. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
[TBL] [Abstract][Full Text] [Related]
8. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
[TBL] [Abstract][Full Text] [Related]
9. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
[TBL] [Abstract][Full Text] [Related]
10. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
Nastase AF; Anand JP; Bender AM; Montgomery D; Griggs NW; Fernandez TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4193-4203. PubMed ID: 30916966
[TBL] [Abstract][Full Text] [Related]
11. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional μ opioid and σ
Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
[TBL] [Abstract][Full Text] [Related]
13. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
[TBL] [Abstract][Full Text] [Related]
16. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
[TBL] [Abstract][Full Text] [Related]
18. Biased Opioid Ligands.
Faouzi A; Varga BR; Majumdar S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
[TBL] [Abstract][Full Text] [Related]
19. SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore.
Henry S; Anand JP; Brinkel AC; McMillan DM; Twarozynski JJ; Loo CE; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2021 Jan; 12(1):216-233. PubMed ID: 33346631
[TBL] [Abstract][Full Text] [Related]
20. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
